News Headlines Article

Hyperion stops diabetes drug trial after study results manipulated
San Francisco Business Times

Hyperion Therapeutics stopped development of a type 1 diabetes drug after employees at an Israeli company it bought three months ago allegedly manipulated data to give a clinical trial a favorable result. The Brisbane company (NASDAQ: HPTX) said Monday that it found that employees of wholly owned subsidiary Andromeda Biotech Ltd. allowed a third-party biostatistics company in Israel to receive unblinded study data and manipulate trial analyses. Hyperion also said the practice continued with another study of the drug.